Trials / Completed
CompletedNCT00772863
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
The Evaluation of Efficacy and Safety of Subsequent Cisplatin and Docetaxel Regimen In The First Line Treatment of Advanced Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and the safety of the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docetaxel and cisplatin | 4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2008-06-01
- First posted
- 2008-10-15
- Last updated
- 2009-10-29
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00772863. Inclusion in this directory is not an endorsement.